1. Home
  2. CRDL vs SPE Comparison

CRDL vs SPE Comparison

Compare CRDL & SPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDL
  • SPE
  • Stock Information
  • Founded
  • CRDL 2017
  • SPE 1993
  • Country
  • CRDL Canada
  • SPE United States
  • Employees
  • CRDL N/A
  • SPE N/A
  • Industry
  • CRDL Biotechnology: Biological Products (No Diagnostic Substances)
  • SPE Finance/Investors Services
  • Sector
  • CRDL Health Care
  • SPE Finance
  • Exchange
  • CRDL Nasdaq
  • SPE Nasdaq
  • Market Cap
  • CRDL 104.5M
  • SPE 158.8M
  • IPO Year
  • CRDL N/A
  • SPE N/A
  • Fundamental
  • Price
  • CRDL $1.25
  • SPE $14.74
  • Analyst Decision
  • CRDL Strong Buy
  • SPE
  • Analyst Count
  • CRDL 3
  • SPE 0
  • Target Price
  • CRDL $9.00
  • SPE N/A
  • AVG Volume (30 Days)
  • CRDL 328.6K
  • SPE 25.4K
  • Earning Date
  • CRDL 11-14-2024
  • SPE 01-01-0001
  • Dividend Yield
  • CRDL N/A
  • SPE 8.55%
  • EPS Growth
  • CRDL N/A
  • SPE N/A
  • EPS
  • CRDL N/A
  • SPE N/A
  • Revenue
  • CRDL N/A
  • SPE N/A
  • Revenue This Year
  • CRDL N/A
  • SPE N/A
  • Revenue Next Year
  • CRDL N/A
  • SPE N/A
  • P/E Ratio
  • CRDL N/A
  • SPE N/A
  • Revenue Growth
  • CRDL N/A
  • SPE N/A
  • 52 Week Low
  • CRDL $0.96
  • SPE $10.26
  • 52 Week High
  • CRDL $3.12
  • SPE $12.59
  • Technical
  • Relative Strength Index (RSI)
  • CRDL 35.65
  • SPE 45.36
  • Support Level
  • CRDL $1.23
  • SPE $14.50
  • Resistance Level
  • CRDL $1.51
  • SPE $15.01
  • Average True Range (ATR)
  • CRDL 0.10
  • SPE 0.27
  • MACD
  • CRDL 0.01
  • SPE 0.01
  • Stochastic Oscillator
  • CRDL 14.75
  • SPE 48.86

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is the United States based closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds. In addition, it also makes investments in construction materials, consumer finance, healthcare equipment and supplies, independent power and renewable electricity producers, insurance, personal products, professional services and real estate investment trusts.

Share on Social Networks: